Cargando…

Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis

BACKGROUND: Some authors have estimated that the incidence of testicular germ cell tumors in individuals with trisomy 21 is more than fivefold higher than that in the general population. OBJECTIVE: This systematic review aimed to estimate the incidence of urological tumors in patients with Down’s sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Korkes, Fernando, Gomez-Bueno, Maria Paula, García-Perdomo, Herney Andrés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499742/
https://www.ncbi.nlm.nih.gov/pubmed/37368086
http://dx.doi.org/10.1007/s11255-023-03656-4
_version_ 1785105772929089536
author Korkes, Fernando
Gomez-Bueno, Maria Paula
García-Perdomo, Herney Andrés
author_facet Korkes, Fernando
Gomez-Bueno, Maria Paula
García-Perdomo, Herney Andrés
author_sort Korkes, Fernando
collection PubMed
description BACKGROUND: Some authors have estimated that the incidence of testicular germ cell tumors in individuals with trisomy 21 is more than fivefold higher than that in the general population. OBJECTIVE: This systematic review aimed to estimate the incidence of urological tumors in patients with Down’s syndrome. STUDY DESIGN: We conducted a search strategy in MEDLINE (OVID), EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to nowadays. We assessed the risk of bias and performed a meta-analysis. Also, the heterogeneity between trials was evaluated by the I(2) test. We completed the subgroup analysis based on the type of urological tumor (testis, bladder, kidney, upper urological tract, penile, retroperitoneum). RESULTS: We found 350 studies by the search strategy. After carefully reviewing, full-text studies were included. 16,248 individuals with Down’s syndrome were included, and 42 patients presented with urological tumors. There was a total incidence of 0.1%, 95%CI (0.06–0.19), I(2) 61%. The most common urological tumor reported was testicular. We found six studies describing 31 events and an overall incidence of 0.19%, 95%CI (0.11–0.33), I(2): 51%. Other studies reported kidney, penile, upper urinary tract, bladder, and retroperitoneum tumors with a very low incidence, 0.02%, 0.06%, 0.03%, 0.11%and 0.07%, respectively. DISCUSSION: Regarding non-testicular urological tumors, we found incidences as low as 0.02% in kidney cancer or 0.03% in the upper-urothelial tract tumors. It is also lower than the general population. Compared to the age of onset of patients, it is also lower than the general population, perhaps related to a shorter life expectancy. As a limitation, we found a high heterogeneity and a lack of information regarding non-testicular tumors. CONCLUSION: There was a very low incidence of urological tumors in people with Down’s syndrome. Testis tumor was the most frequently described in all cohorts and within a normal distribution range.
format Online
Article
Text
id pubmed-10499742
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-104997422023-09-15 Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis Korkes, Fernando Gomez-Bueno, Maria Paula García-Perdomo, Herney Andrés Int Urol Nephrol Urology - Original Paper BACKGROUND: Some authors have estimated that the incidence of testicular germ cell tumors in individuals with trisomy 21 is more than fivefold higher than that in the general population. OBJECTIVE: This systematic review aimed to estimate the incidence of urological tumors in patients with Down’s syndrome. STUDY DESIGN: We conducted a search strategy in MEDLINE (OVID), EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to nowadays. We assessed the risk of bias and performed a meta-analysis. Also, the heterogeneity between trials was evaluated by the I(2) test. We completed the subgroup analysis based on the type of urological tumor (testis, bladder, kidney, upper urological tract, penile, retroperitoneum). RESULTS: We found 350 studies by the search strategy. After carefully reviewing, full-text studies were included. 16,248 individuals with Down’s syndrome were included, and 42 patients presented with urological tumors. There was a total incidence of 0.1%, 95%CI (0.06–0.19), I(2) 61%. The most common urological tumor reported was testicular. We found six studies describing 31 events and an overall incidence of 0.19%, 95%CI (0.11–0.33), I(2): 51%. Other studies reported kidney, penile, upper urinary tract, bladder, and retroperitoneum tumors with a very low incidence, 0.02%, 0.06%, 0.03%, 0.11%and 0.07%, respectively. DISCUSSION: Regarding non-testicular urological tumors, we found incidences as low as 0.02% in kidney cancer or 0.03% in the upper-urothelial tract tumors. It is also lower than the general population. Compared to the age of onset of patients, it is also lower than the general population, perhaps related to a shorter life expectancy. As a limitation, we found a high heterogeneity and a lack of information regarding non-testicular tumors. CONCLUSION: There was a very low incidence of urological tumors in people with Down’s syndrome. Testis tumor was the most frequently described in all cohorts and within a normal distribution range. Springer Netherlands 2023-06-27 2023 /pmc/articles/PMC10499742/ /pubmed/37368086 http://dx.doi.org/10.1007/s11255-023-03656-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Urology - Original Paper
Korkes, Fernando
Gomez-Bueno, Maria Paula
García-Perdomo, Herney Andrés
Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis
title Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis
title_full Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis
title_fullStr Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis
title_full_unstemmed Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis
title_short Incidence of urological tumors in Down’s syndrome: a systematic review and meta-analysis
title_sort incidence of urological tumors in down’s syndrome: a systematic review and meta-analysis
topic Urology - Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499742/
https://www.ncbi.nlm.nih.gov/pubmed/37368086
http://dx.doi.org/10.1007/s11255-023-03656-4
work_keys_str_mv AT korkesfernando incidenceofurologicaltumorsindownssyndromeasystematicreviewandmetaanalysis
AT gomezbuenomariapaula incidenceofurologicaltumorsindownssyndromeasystematicreviewandmetaanalysis
AT garciaperdomoherneyandres incidenceofurologicaltumorsindownssyndromeasystematicreviewandmetaanalysis